Does USTEKINUMAB Cause Bladder transitional cell carcinoma? 19 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Bladder transitional cell carcinoma have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.0% of all adverse event reports for USTEKINUMAB.
19
Reports of Bladder transitional cell carcinoma with USTEKINUMAB
0.0%
of all USTEKINUMAB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From USTEKINUMAB?
Of the 19 reports, 6 (31.6%) required hospitalization, and 1 (5.3%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 19 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which USTEKINUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE